

CORRECTION

[View Article Online](#)
[View Journal](#) | [View Issue](#)



Cite this: *Nat. Prod. Rep.*, 2021, **38**, 1221

DOI: 10.1039/d1np90001c

rsc.li/npr

Correction: Natural polyenic macrolactams and polycyclic derivatives generated by transannular pericyclic reactions: optimized biogenesis challenging chemical synthesis

Rosana Alvarez and Angel R. de Lera*

Correction for 'Natural polyenic macrolactams and polycyclic derivatives generated by transannular pericyclic reactions: optimized biogenesis challenging chemical synthesis' by Rosana Alvarez *et al.*, *Nat. Prod. Rep.*, 2021, DOI: 10.1039/d0np00050g.






The authors regret that there are errors present in the article as detailed below.

Firstly, within the discussion of compounds **28c** and **23c** in Section 2.1.1.2. Polycyclic heronamides, the text “namely human colon cancer (HCT116 carcinoma and Caco2 adenocarcinoma)” should be “namely human colon cancer (Caco-3 adenocarcinoma and Caco-2 adenocarcinoma)”.



Secondly, within Fig. 3 and Scheme 7, a methyl substituent is missing from compound **29**, heronamide H. The corrected versions of Fig. 3 and Scheme 7 are displayed below.

A

**29**, heronamide H**30**, heronamide I**31**, heronamide J**32**, heronamide K**33**, heronamide L

B




**34**, niveamide B**35**, niveamide

Fig. 3 (A) Polycyclic compounds **29**–**33** derived from additional reactions (including electrocyclic reactions) of naturally-occurring 20-membered ring polyenic macrolactams.⁷⁰ (B) Putative biogenetic intermediates niveamide B **34** (ref. 70) and unsaturated analog niveamide **35**.⁷³






Scheme 7 Transannular ring-opening reaction of the epoxide **41** derived from **37c** (itself arising from putative biogenetic precursor 20-membered ring polyenic macrolactam BE-14106 (GT32-A) **22c**) to afford heronamide H **29**.⁷⁰

Thirdly, within Scheme 24, the arrow leading from compound **158** is incorrectly labelled with IdnO1. Also, the arrow leading from compound **156** that is labelled with SipO1 and AurO1 should not be present. The corrected version of Scheme 24 is displayed below.






Scheme 24 Biogenesis of loading unit (A), primary macrolactams (B) and 24-membered ring polyenic macrolactams incednine **147** (ref. 147) and sipanmycin A (auroramycin) **149a** (C).^{32,141,142,146}



Additionally, within Scheme 58A, there is an error within the name displayed for compound 9. “(2*S*,3*R*)-3-Methyl aspartic acid” should be “(2*S*,3*S*)-3-methyl aspartic acid”. The corrected version of Scheme 58 is displayed below.



Scheme 58 Putative biogenesis of loading unit (A) and polyenic macrolactams sceliphrolactam **404** and niizalactam C (tripartilactam) **409** (B).^{238,240}

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

